Rebecca Mattison, MD
Endocrinology · Edina, MNNPI 1093775736
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 133 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. Among endocrinology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 133 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$269
- Amgen$232
- AstraZeneca$205
- Insulet Corporation$165
- Abbott$142
- Ipsen Biopharmaceuticals, Inc$112
- plus $1K from 28 others
What the payments were for
- Food & beverage$2,246100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 14 | $269 |
| Amgen(2 entities) | 16 | $232 |
| AstraZeneca(2 entities) | 11 | $205 |
| Insulet Corporation | 9 | $165 |
| Abbott | 8 | $142 |
| Ipsen Biopharmaceuticals, Inc | 4 | $112 |
| Boehringer Ingelheim | 6 | $100 |
| Dexcom, Inc. | 6 | $86 |
| Esperion Therapeutics, Inc. | 5 | $73 |
| Radius Health, Inc. | 5 | $70 |
| Recordati_rare_diseases_inc. | 3 | $60 |
| Antares Pharma, Inc. | 4 | $60 |
| Mannkind Corporation | 3 | $59 |
| Ascensia Diabetes Care US Inc. | 3 | $50 |
| Corcept Therapeutics | 2 | $48 |
| Novo Nordisk | 4 | $46 |
| Bayer | 3 | $46 |
| Chiesi USA, Inc. | 2 | $37 |
| Lilly USA, LLC | 2 | $36 |
| Pfizer | 2 | $35 |
| Valeritas, Inc. | 2 | $33 |
| Novartis | 2 | $31 |
| Kyowa Kirin, Inc. | 2 | $29 |
| Xeris Pharmaceuticals, Inc. | 2 | $29 |
| Lifescan, Inc. | 2 | $28 |
| Companion Medical, Inc. | 2 | $27 |
| Merck | 2 | $24 |
| Zealand Pharma US, Inc. | 1 | $19 |
| Halozyme Inc | 1 | $19 |
| Ionis Pharmaceuticals, Inc. | 1 | $17 |
| Cequr Corporation | 1 | $17 |
| Sequel Med Tech, LLC | 1 | $17 |
| Rhythm Pharmaceuticals, Inc. | 1 | $15 |
| Tandem Diabetes Care, Inc. | 1 | $12 |
How this compares
$2,246 in reported general payments places this provider in the 95th percentile of 35 endocrinology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ForteoTeriparatide | 64 | $292,818 |
| Teriparatide | 89 | $226,747 |
| OzempicSemaglutide | 121 | $174,251 |
| MounjaroTirzepatide | 96 | $133,343 |
| TymlosAbaloparatide | 29 | $93,389 |
| JardianceEmpagliflozin | 71 | $83,316 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 48 | $82,902 |
| TrulicityDulaglutide | 39 | $62,082 |
| FarxigaDapagliflozin Propanediol | 47 | $42,535 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 53 | $32,989 |
| InvokanaCanagliflozin | 29 | $23,133 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 111 | $19,576 |
| SynthroidLevothyroxine Sodium | 206 | $18,856 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $18,554 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 17 | $18,546 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCForteo, Mounjaro, Trulicity, Humalog, Humulin 70-30 | $36 | $503,999262 claims |
| Novo NordiskOzempic, Novolog, Tresiba | $46 | $189,280174 claims |
| Radius Health, Inc.Tymlos | $70 | $93,38929 claims |
| Boehringer IngelheimJardiance | $100 | $83,31671 claims |
| AstraZenecaFarxiga | $205 | $42,53547 claims |
| MerckJanuvia | $24 | $15,36817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 35 endocrinology providers in Minnesota.
Other endocrinology in Edina
- John SchempfEdina$0
- Anne RosenbergEdina$0
- Haitham Abu LebdehRochester$0
- Shalamar SibleyMinneapolis$0
- Hind AlameddineMinneapolis$0
- Susanne TrostMinneapolis$0
- Suhail Saad-OmerRochester$0
- Gregory MuchaSaint Paul$0
- Sofronio RamirezSt Louis Park$0
- Rashi SandoojaRochester$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.